Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells

Clinical and Experimental Metastasis

Volumn 29, Issue 4, 2012, Pages 349-358

  Castilla, Carolina ^a   Flores, M Luz ^a   Conde, José M ^a   Medina, Rafael ^a   Torrubia, Francisco J ^a   Japón, Miguel A ^a   Sáez, Carmen ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Cell cycle; Invasion; PTPL1; PTPN13; uPA system

Indexed keywords

ALPHA6 INTEGRIN; COMPLEMENTARY DNA; CYCLIN B1; CYCLIN E; HISTONE H3; MATRIGEL; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; OSTEOPONTIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; SECURIN; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL INVASION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA6; MALE; NEOPLASM INVASIVENESS; OSTEOPONTIN; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84859731558     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9455-7     Document Type: Article

References (36)

1. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11:1388-1413
2. Morrissey C, Vessella RL (2007) The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 101(4):873-886 (Pubitemid 47040869)
3. Wittekind C, Neid M (2005) Cancer invasion and metastasis. Oncology 69(Suppl 1):14-16 (Pubitemid 41433536)
4. Erdmann KS (2003) The protein tyrosine phosphatase PTP-basophil/basophil- like. Interacting proteins and molecular functions. Eur J Biochem 270(24):4789-4798
5. Abaan OD, Toretsky JA (2008) PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev 27(2):205-214
6. Freiss G, Chalbos D (2011) PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anticancer Agents Med Chem 11(1):78-88
7. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304(5674):1164-1166 (Pubitemid 38661854)
8. Herrmann L, Dittmar T, Erdmann KS (2003) The protein tyrosine phosphatase PTP-BL associates with the midbody and is involved in the regulation of cytokinesis. Mol Biol Cell 14(1):230-240 (Pubitemid 36106032)
9. Nedachi T, Conti M (2004) Potential role of protein tyrosine phosphatase nonreceptor type 13 in the control of oocyte meiotic maturation. Development 131(20):4987-4998 (Pubitemid 39485356)
10. Zhu JH, Chen R, Yi W, Cantin GT, Fearns C, Yang Y, Yates JR 3rd, Lee JD (2008) Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signalling. Oncogene 27(18):2525-2531 (Pubitemid 351550886)
11. Lai YJ, Lin WC, Lin FT (2007) PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J Biol Chem 282(33):24381-24387
12. Hoover AC, Strand GL, Nowicki PN, Anderson ME, Vermeer PD, Klingelhutz AJ, Bossler AD, Pottala JV, Hendriks WJ, Lee JH (2009) Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 28(45):3960-3970
13. Glondu-Lassis M, Dromard M, Lacroix-Triki M, Nirdé P, Puech C, Knani D, Chalbos D, Freiss G (2010) PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res 70(12):5116-5126
14. Domínguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Toro JA (1998) hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17(17):2187-2193
15. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
16. Hiendlmeyer E, Regus S, Wassermann S, Hlubek F, Haynl A, Dimmler A, Koch C, Knoll C, van Beest M, Reuning U, Brabletz T, Kirchner T, Jung A (2004) Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res 64(4):1209-1214 (Pubitemid 38235582)
17. Wang Q, Sun ZX, Allgayer H, Yang HS (2010) Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene 29(1):128-138
18. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153-166
19. Maga G, HubscherU(2003) Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 116(Pt 15):3051-3060 (Pubitemid 37038954)
20. Ramos-Morales F, Domínguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, Tortolero M (2000) Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19(3):403-409 (Pubitemid 30077341)
21. Hayashi-Takanaka Y, Yamagata K, Nozaki N, Kimura H (2009) Visualizing histone modifications in living cells: spatiotemporal dynamics of H3 phosphorylation during interphase. J Cell Biol 187(6):781-790
22. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57(1):25-40 (Pubitemid 30105328)
23. Duffy MJ (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48(8):1194-1197
24. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N (2004) Cathepsin B, plasminogen activator inhibitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 24(6):4147-4161 (Pubitemid 40468721)
25. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, Cher ML (2008) Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 10(5):439-449 (Pubitemid 351657386)
26. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF (2009) Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 55(5):1124-1133
27. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS (2005) RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280(43):36529-36540 (Pubitemid 41633927)
28. Rabinovitz I, Nagle RB, Cress AE (1995) Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 13(6):481-491
29. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel KM, Dalkin BL, Nagle RB (2002) Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 4(3):243-254 (Pubitemid 34525256)
30. Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE (2007) Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp Cell Res 313(6):1080-1089 (Pubitemid 46427820)
31. Ports MO, Nagle RB, Pond GD, Cress AE (2009) Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res 69(12):5007-5014
32. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79-87 (Pubitemid 43247403)
33. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y (2006) Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 118(9):2255-2261
34. Caruso DJ, Carmack AJ, Lokeshwar VB, Duncan RC, Soloway MS, Lokeshwar BL (2008) Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 14(13):4111-4118
35. Das R, Mahabeleshwar GH, Kundu GC (2004) Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279(12):11051-11064 (Pubitemid 38401597)
36. Erdmann KS, Kuhlmann J, Lessmann V, Herrmann L, Eulenburg V, Müller O, Heumann R (2000) The adenomatous polyposis coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain. Oncogene 19(34):3894-3901 (Pubitemid 30658980)